Olopatadine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Olopatadine: From Allergic Conjunctivitis and Rhinitis to Rosacea Conjunctivitis
One-Sentence Summary
Olopatadine is an antihistamine and mast cell stabiliser, originally used for allergic rhinitis, vasomotor rhinitis, and atopic, papillary and vernal conjunctivitis. The TxGNN model predicts it may be effective for rosacea conjunctivitis, but there are currently 0 clinical trials and 0 publications supporting this specific prediction. The score is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, atopic conjunctivitis, papillary conjunctivitis, vernal conjunctivitis |
| Predicted New Indication | Rosacea conjunctivitis |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data compiled for this report. Based on known information, olopatadine is an H1 antagonist and mast cell stabiliser. Its efficacy in allergic conjunctivitis is established, and it is marketed in Singapore as eye drops and as a nasal spray combination.
The link to rosacea conjunctivitis is weak. Ocular rosacea is driven mainly by meibomian gland dysfunction, inflammation and Demodex mites, with only a limited allergic or histaminergic component. Any benefit from olopatadine would therefore be indirect, for example relieving a coexisting allergic component.
The very high TxGNN score (0.994) most likely reflects similarity to the approved conjunctivitis indications rather than a distinct mechanistic signal.
Other predictions in the same ranking show the same pattern. Examples are punctate epithelial keratoconjunctivitis, conjunctival folliculosis, chronic follicular conjunctivitis and blepharoconjunctivitis. Only their allergic subsets are plausible targets. Viral or infectious forms (acute hemorrhagic conjunctivitis, pseudomembranous conjunctivitis) have little mechanistic rationale. All of these are at L4–L5 and are on Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for rosacea conjunctivitis.
For the second-ranked prediction, punctate epithelial keratoconjunctivitis, one case report is linked. It is PMID 22606467 (2011, Case Reports in Ophthalmological Medicine), on limbitis secondary to autologous serum eye drops in atopic keratoconjunctivitis. Olopatadine appears only as part of the background treatment, so this is not evidence of efficacy.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13961P | Pataday® Sterile Ophthalmic Solution 0.2% | Solution, sterile | Not specified in the data |
| SIN15242P | PAZEO Ophthalmic Solution 0.7% | Solution, sterile | Not specified in the data |
| SIN16569P | OLOPAN Ophthalmic Solution 0.1% w/v | Solution | Not specified in the data |
| SIN15526P | ALERCHEK Ophthalmic Solution 0.2% | Solution, sterile | Not specified in the data |
| SIN15527P | ALERCHEK Ophthalmic Solution 0.1% | Solution, sterile | Not specified in the data |
Seven valid single-ingredient licences are registered, and none are cancelled. The two others are PATANOL Sterile Ophthalmic Solution 0.1% (SIN10485P) and RYALTRIS Nasal Spray 600/25 mcg (SIN16523P).
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for safety information.
- Knowledge-graph contraindication signals (not label text): lower respiratory tract disease, paranasal sinus disease, nasal cavity disease, upper respiratory tract disease. These should be verified against the product labels.
- Drug Interactions: The interaction query returned 100 records, all with severity "Unknown". Examples include pantoprazole, doxycycline, clotrimazole, metformin, omeprazole, cimetidine, prednisone, epinephrine and simvastatin. Clinical significance cannot be judged from this data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on model similarity (L5). There are no trials or literature on olopatadine in rosacea conjunctivitis, and the disease is driven mainly by non-histaminergic mechanisms. Olopatadine is already marketed in Singapore, but no label indication supports this use.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website (a blocking gap for safety screening)
- Detailed mechanism of action data (e.g. from DrugBank)
- Clinical or observational evidence of olopatadine in ocular rosacea, ideally in patients with a coexisting allergic component
- Confirmation of the approved indication text for each Singapore licence
- Review of whether any of the other predicted conjunctival conditions with an allergic subset has stronger support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.